Cullen/Frost Bankers’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.52M | Buy |
10,795
+78
| +0.7% | +$25.4K | 0.04% | 216 |
|
|
2025
Q1 | $2.89M | Buy |
10,717
+78
| +0.7% | +$21.1K | 0.04% | 224 |
|
|
2024
Q4 | $2.5M | Buy |
10,639
+4
| +0% | +$941 | 0.03% | 230 |
|
|
2024
Q3 | $2.92M | Buy |
10,635
+80
| +0.8% | +$22K | 0.04% | 222 |
|
|
2024
Q2 | $2.56M | Sell |
10,555
-7
| -0.1% | -$1.7K | 0.04% | 227 |
|
|
2024
Q1 | $1.58M | Buy |
10,562
+13
| +0.1% | +$1.94K | 0.02% | 266 |
|
|
2023
Q4 | $2.02M | Hold |
10,549
| – | – | 0.03% | 241 |
|
|
2023
Q3 | $1.87M | Hold |
10,549
| – | – | 0.03% | 240 |
|
|
2023
Q2 | $2M | Hold |
10,549
| – | – | 0.03% | 244 |
|
|
2023
Q1 | $2.11M | Hold |
10,549
| – | – | 0.04% | 240 |
|
|
2022
Q4 | $2.51M | Hold |
10,549
| – | – | 0.05% | 225 |
|
|
2022
Q3 | $2.11M | Sell |
10,549
-400
| -4% | -$80K | 0.05% | 221 |
|
|
2022
Q2 | $1.6M | Hold |
10,949
| – | – | 0.04% | 254 |
|
|
2022
Q1 | $1.79M | Buy |
10,949
+400
| +4% | +$65.3K | 0.03% | 249 |
|
|
2021
Q4 | $1.79M | Hold |
10,549
| – | – | 0.03% | 251 |
|
|
2021
Q3 | $1.99M | Hold |
10,549
| – | – | 0.04% | 246 |
|
|
2021
Q2 | $1.79M | Sell |
10,549
-1,176
| -10% | -$199K | 0.04% | 258 |
|
|
2021
Q1 | $1.66M | Hold |
11,725
| – | – | 0.04% | 257 |
|
|
2020
Q4 | $1.52M | Sell |
11,725
-8,284
| -41% | -$1.08M | 0.04% | 250 |
|
|
2020
Q3 | $2.91M | Sell |
20,009
-840
| -4% | -$122K | 0.07% | 192 |
|
|
2020
Q2 | $3.09M | Sell |
20,849
-1,674
| -7% | -$248K | 0.08% | 191 |
|
|
2020
Q1 | $2.45M | Buy |
+22,523
| New | +$2.45M | 0.09% | 189 |
|